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Inhibition of platelet-derived growth factor receptor tyrosine kinase by
atrial natriuretic peptide. Atrial natriuretic peptide (ANP) is known to
suppress platelet-derived growth factor (PDGF)-stimulated proliferation
of rat cultured vascular smooth muscle cells. The present study examined
whether ANP inhibits the PDGF receptor (PDGFR) tyrosine kinase
activation, an initial event for PDGF cellular signaling. ANP reduced the
in vivo tyrosine phosphorylation of PDGFR stimulated by PDGF in a
dose-dependent manner. This effect was not due to the reduction in
PDGFR protein as detected by immunoblot analysis. 8-Bromo-cyclic
GMP, a membrane-permeable 3',5'-cyclic monophosphate (cGMP) deriv-
ative, mimicked the action of ANP. HS-142-1, an antagonist for guanylate
cyclase A (GC-A) and B, co-incubated with ANP, restored the PDGF-
induced PDGFR autophosphorylation. The effect of ANP was also
observed in the presence of a protein tyrosine phosphatase inhibitor,
sodium orthovanadate. To confirm that ANP exerts its action by inhibiting
protein tyrosine kinase (PTK), an in vitro kinase assay was performed.
Cyclic GMP inhibited PTK activity of PDGFR partially purified by lectin
affinity chromatography. In contrast, PTK activity in immobilized PDGFR
immunocomplexes was not inhibited by cGMP. However, exogenous
cGMP dependent protein kinase (PKG) reduced the PTK activity in the
presence of cGMP. These results demonstrate that ANP suppresses
PDGFR PTK through GC-A probably by activating PKG. This may be an
important mechanism by which ANP exerts its anti—proliferative action
antagonizing PDGF.
Vascular smooth muscle cell proliferation is one of the key
events in the pathogenesis of atherosclerosis, hypertension, and
restenosis after angioplasty [1]. Various growth factors and vaso-
active peptides are implicated to play a role in these processes.
PDGF is the most potent mitogen for mesenchymal cells including
vascular smooth muscle cells [2]. In this regard, detailed know!-
edge of cellular signaling for PDGF and the inhibition of the
cascade draws particular attention as potential use in the treat-
ment of disease.
Signal transduction through PDGFR requires ligand activation
of receptor, which involves receptor dimerization, intrinsic recep-
tor tyrosine kinase activation, and autophosphorylation of recep-
tor. Autophosphorylation on multiple tyrosine residues alters the
conformation of PDGFR and increases the ability to bind and
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phosphorylate other proteins [3, 4]. These proteins include phos-
pholipase C y [5], ras GTPase-activating protein (GAP) [6],
phosphatidylinositol 3-kinase (P13-kinase) [71, and an adaptor
molecule She [8]. Recent works suggest that complexes of She,
growth factor receptor-bound protein 2 (Grb2), and the guanine
nucleotide releasing factor son-of-sevenless (SOS) leads to the
activation of ras-mitogen-activated protein kinase (MAPK) cas-
cade, a critical step in induction of mitogenesis and proliferation
[8—10].
Atrial natriuretic peptide is a natriuretic, diuretic, and vasodi-
lative polypeptide released from cardiac atria and is considered to
play an important role in the regulation of body fluid homeostasis
[11]. In recent years, however, ANP has also been demonstrated
to inhibit cellular growth and proliferation in a variety of cell lines
including vascular smooth muscle cells [12]. Of the three types of
receptors for ANP, guanylate cyclase A (GC-A) and B (GC-B)
have intracellular guanylate cyclase domains and are responsible
for the generation of cGMP [13]. ANP preferentially binds to and
activates GC-A, while GC-B is selectively stimulated by C-type
natriuretic peptide (CNP) [14]. Since nitric oxide and cGMP
analogs have also been shown to inhibit proliferation and hyper-
trophy of cultured vascular smooth muscle cells [12, 15, 16], GC-A
is considered to mediate, at least in part, the growth-inhibitory
action of ANP. However, the intracellular mechanism(s) by which
cGMP exerts an anti-proliferative effect is totally unknown.
In particular, ANP has been shown to antagonize the prolifer-
ative action of PDGF in vascular smooth muscle cells [15].
Therefore, the present study examined whether the anti-prolifer-
ative action of ANP and cGMP involves the tyrosine phosphory-
lation of PDGFR, an initial step for PDGF cellular signaling.
METHODS
Materials
Human recombinant PDGF-BB, C-ANP421, cGMP, 8-bromo-
cGMP, nitroblue tetrazolium, 5-bromo-4-chloro-3-indolyl phos-
phate, and bovine serum albumin (BSA) were purchased from
Sigma (St. Louis, MO, USA). ANP (rat, 1-28) was from Peptide
Institute Inc. (Osaka, Japan). Monoclonal anti-phosphotyrosine
antibody (PY2O-alkalinc phosphatase conjugate) was from Trans-
duction Laboratories (Lexington, KY, USA). Anti-human PDGF
type p receptor was from Upstate Biotechnology Inc. (Lake
Placid, NY, USA). cGMP-dependent protein kinase purified from
bovine lung was from Promega (Madison, WI, USA). Wheat germ
lectin-Scpharose 6MB and protein A Sepharose 4 fast flow were
from Pharmacia (Tokyo, Japan). IgGsorb was from The Enzyme
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Center (Maiden, MA, USA). N,N',N"-triacetylchitotriose was
from EY Laboratories Inc. (San Mateo, CA, USA). Dulbecco's
modified Eagle's medium (DMEM), fetal bovine serum (FBS),
collagenase, penicillin, streptomycin, trypsin-EDTA were from
Gibco Laboratories (Grand Island, NY, USA). HS-142-1 was a
gift from Kyowa Hakko Kogyo Co., Ltd. [3H] thymidine and the
cyclic GMP [1251] assay system were from Amersham (Tokyo,
Japan).
Cell culture
Rat aortic smooth muscle cells were isolated and cultured from
100 g to 150 g male Sprague-Dawley rats by enzymatic dispersion
as previously described [17]. Cells were grown in DMEM contain-
ing 10% FBS, 100 units/mI penicillin, and 100 mg/mi streptomycin.
Since the expression of both GC-A and PKG diminishes with
passage in culture [17, 18], only early passages of cells (passages 3
to 5) were used unless otherwise indicated. Confluent cells were
deprived of serum for 48 hours and stimulated with PDGF-BB (10
ng/ml, final concentration) for 10 minutes at 37°C with or without
various agents. Cells were washed with cold phosphate-buffered
saline and lysed in solubilization buffer containing 20 mivi Hepes,
pH 7.2, 1% Triton-100, 10% glycerol, 20 m sodium fluoride,
I m'vi sodium orthovanadate, 1 mi phenylmethylsuifonyl fluoride.
Insoluble material was removed by centrifugation (10,500 x g, 10
miii). Cleared lysates were resolved by SDS-PAGE, and trans-
ferred to PVDF membranes (Immobilon; Millipore Corp, Bed-
ford, MA, USA) and immunoblotted.
[HI thymidine incorporation
Cells were grown in a 24 well dish and then made quiescent by
serum deprivation. After 48 hours, cells were treated with ANP
10 to 10—6 M or vehicle. Then 1 LCi [3H] thymidine was added
to wells with PDGF 10 ng/ml. After incubation for further 24
hours, cells were washed with ice-cold phosphate-buffered saline
and 5% trichioroacetic acid, solubilized in 0.2 N NaOH and
counted using a liquid scintillation counter.
Cyclic GMP generation studies
Cells were preincubated with isohutylmethylxanthine 1 mM for
two minutes. Then ANP was added for 10 minutes in concentra-
tions of i0 to 106 El. The reactions were terminated by adding
ice-cold 10% trichloroacetic acid and cGMP determined by
radioimmunoassay as previously described [19].
Immunoblot analysis
Nonspecific binding sites were blocked in TBS buffer (10 mM
Tris-Cl, pH 7.4, 0.15 M NaC1) containing 5% BSA overnight at 4°C
or for one hour at 25°C. Antibodies were added to TBS with 5%
BSA in saturating titers and incubated with mixing for two hours
at 25°C. Blots were washed two times, then developed (anti-
phosphotyrosine antibody). For analysis with PDGFR antiserum,
blots were further incubated with goat anti-rabbit IgG/alkaline
phosphatase conjugate for one hour with mixing, and then
washed. Membranes were washed once in substrate buffer (0.1 M
Tris-CI, pH 9.5, 0.1 M NaCl, and 5 mvi MgCl2), and then
developed by the addition of fresh substrate (20 mg of nitroblue
tetrazolium in 60 ml of substrate buffer, mixed immediately before
blot exposure with 10 mg of 5-bromo-4-ehloro-3-indolyl phos-
phate in 200 d of N,N dimethylformamide). Alternatively, bound
antibodies were detected using the ECL Western blotting system
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Fig. 1. Inhibition of PDGF-stimulated [3H] thymidine incorporation by
ANP in rat vascular smooth muscle cells. Results are expressed as
percentage of control, defined as thymidune incorporation in the presence
of 10 ng/ml PDGF. Results are mean SE of three experiments. *p < 0.05
versus contol.
from Amersham. Blots were scanned and quantitatively analyzed
using NIH Image.
Lectin and immune affinity steps and tyrosine kinase assay
Cell lysates were incubated with wheat germ lectun-Sepharose
6MB with continuous mixing for two hours at 4°C; lectin affinity
recovered proteins were eluted in kinase buffer (20 mtvi HEPES,
20 mvi MnCl2, 150 m'vi NaCI, 0.1% Triton-100, 1 mrvt sodium
orthovanadate, 1 mivi phenylmethylsulfonyl fluoride) containing 3
mM N,N ' ,N"-triacetylchitotriose. Alternatively, detergent cell ex-
tracts were precleared with IgGsorb, and antiserum added (anti-
human PDGF type 13 receptor). Immunoprecipitates were col-
lected by incubation with protein A-Sepharose for 30 minutes and
then washed. PDGFR tyrosine kinase activity was assayed in a
final volume of 50 tl kinase buffer containing 20 mM MgCl2.
PDGF (50 ng/ml) was added for 15 minutes at 0°C prior to
addition of 20 JLM ATP. Cyclic GMP (2 LM), PKG (0.5 units/ml)
or both agents were added at the same time as ATP. After 30
minutes of incubation at 22°C, reactions were stopped by addition
of 13 l of 5 X Laemmli SDS-PAGE sample buffer. Samples were
then boiled for four minutes, electrophoresed and transferred.
Immunoblotting was performed as described above.
Statistical analysis
The results are expressed as mean SE, Statistical analysis was
performed with ANOVA followed by multiple comparisons as
appropriate. Differences were considered statistically significant
at P < 0.05.
RESULTS
Effect of ANP on [3H] thymidine incorporation
ANP inhibited the PDGF-stimuiated [3H] thymidine incorpo-
ration in a dose-dependent manner in vascular smooth muscle
cells (10—6 M 47 3%, iO M 76 1%, 10 M 99 17% of
PDGF alone, respectively, N = 3; Fig. 1). These results are in
accordance with previous studies [151.
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Fig. 2. Effect of ANP on cGMP generation. Rat aortic vascular smooth
muscle cells were preincubated with isobutylmethylxanthine 1 m for two
minutes. Then ANP was added for 10 minutes in concentrations of 10_s to
106 M. The reactions were terminated by adding trichloroacetic acid and
cGMP determined by radioimmunoassay. Results are mean SE of six
experiments.
Effect of ANP on cGMP generation
ANP increased the intracellular cGMP generation in a dose-
dependent manner (10 to 10_6 M) after 10 minutes of incuba-
tion in vascular smooth muscle cells (Fig. 2).
Effects of ANP and 8-bromo-cGMP on PDGFR
autophosphorylation in vivo
A 180 kDa protein was phosphorylated with PDGF stimulation
on tyrosine residues (Fig. 3A). This protein was confirmed to be
PDGFR by immunoprecipitation with anti-phosphotyrosine fol-
lowed by immunoblotting with anti-PDGFR (data not shown).
Increasing concentrations of ANP resulted in the progressive
reduction in the tyrosine phosphorylation of PDGFR (106 M
46 6%, iO M 66 2%, iO M 85 15% of PDGF alone,
respectively, N = 3; Fig. 3 A, C). The dose-dependency of ANP
was similar to that for the cGMP generation (Fig. 2). HS-142-1
(1 mg/mi), a selective antagonist for GC-A and GC-B [20],
completely abolished the effect of ANP on PDGFR phosphory-
lation (138 26% of PDGF alone, N = 3; Fig. 3 A, C).
C-ANP4.,1, a ring-deleted analog of ANP, which binds to only the
clearance receptor of ANP [211, had no effect on PDGFR
autophosphorylation (Fig. 3B). On the other hand, a membrane-
permeable analog of cGMP, 8-bromo-cGMP (102 M) reduced
the autophosphorylation of PDGFR to a similar extent as ANP
106 M (59 1% of PDGF alone, N = 3; Fig. 3 B, C). The
suppression of PDGFR autophosphorylation by ANP in these
experiments was not due to a decrease in PDGFR protein as
shown by immunoblotting with anti-PDGF 13 receptor antiserum.
Tyrosine phosphorylation of 110 kDa and 66 kDa protein was
also inhibited by ANP (Fig. 3A).
I next examined whether the reduced PDGFR autophosphor-
ylation is due to suppressed PDGFR PTK or increased protein
tyrosine phosphatase (PTPase) activity. Thus, the effect of ANP
on PDGFR phosphorylation was studied under PTPase inhibitor,
sodium orthovanadate (vanadate) 100 .tM. As shown in Figure
3D, PDGFR was more tyrosine phosphorylated in the presence of
vanadate than in absence of vanadate. ANP 106 M reduced
PDGFR autophosphorylation by 63%, a degree similar to the
previous experiments.
Effects of cGMP and PKG on PDGFR PTK activity
To further investigate the mechanism for the cGMP-dependent
inhibition of PDGFR autophosphorylation, in vitro PTK assay was
performed using PDGFR partially purified by lectin affinity
chromatography. Cyclic GMP, as well as exogenous PKG in the
presence of cGMP (Fig. 4 A, B), inhibited the PDGFR PTK by
approximately 70%. Since vanadate was included in the kinase
reaction, the possibility of the activation of PTPase present in the
receptor preparation was ruled out. However, the result does not
differentiate whether cGMP directly inhibits PDGFR PTK or
indirectly through activating the PKG that may be present in the
PDGFR preparation. The use of passaged cells that lost PKG
gave a unique opportunity to differentiate these two possibilities
[17]. Thus, PDGFR was purified from passaged cells (passages 8
to 9) that did not respond to ANP or 8-bromo-cGMP in vivo (Fig.
4C). In this preparation, cGMP had no effect on PTK activity
(104 6% vs. baseline activity, N = 3; Fig. 4 D, E). By contrast,
exogenous PKG in the presence of cGMP reduced the PTK
activity (65 5% vs. baseline, N = 3). Since PKG had no effect in
the absence of cGMP on PTK activity (Fig. 4 A, B), the effect of
PKG is considered to be specific.
To further confirm that PKG is responsible for the inhibition of
PDGFR PTK, kinase assay was performed in Sepharose matrix-
immobilized PDGFR immunocomplexes, in an attempt to avoid
contamination with other proteins. Similarly to the previous
experiments, cGMP alone had no effect on PTK activity, while
exogenous PKG inhibited it in the presence of cGMP (Fig. 4E).
DISCUSSION
The findings presented here demonstrate that ANP inhibits
PDGFR autophosphorylation in vascular smooth muscle cells.
This effect was mimicked by 8-bromo-cGMP and abolished by an
antagonist for guanylate cyclase A, suggesting a cGMP-dependent
mechanism. In addition, the dose-dependency of the inhibitory
effect of ANP on PDGFR phosphorylation was correlated with
the inhibition of DNA synthesis and the increase in intracellular
cGMP. The observed effect was considered to be due to the
inhibition of PDGFR PTK rather than the activation of PTPase,
since the effect of ANP was also seen in the presence of PTPase
inhibitor. PDGFR protein was not affected by ANP. Therefore,
the mechanism for the inhibition of PTK by ANP is either an
alteration in PDGF binding, dimerization, or a direct effect on
catalytic activity.
ANP has been shown to suppress growth in several cell lines
including vascular smooth muscle cells [12]. Although some
studies suggest that the growth-inhibitory action of ANP is
mediated through C-receptor, which lacks the guanylate cyclase
structure [22], most of the previous studies indicate that cGMP is
responsible for the effects. Thus, other cGMP generating agents
such as nitrovasodilators and CNP have been demonstrated to
inhibit mitogenesis [16, 23]. In these studies, 8-bromo-cGMP, a
membrane permeable cGMP analog, mimicked the action of
ANP. Furthermore, HS-142-1, a selective antagonist for GC-A
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Fig. 3. Effects of ANP and 8-bromo-cGMP on PDGFR autophosphorylation in vivo. (A) Rat aortic vascular smooth muscle cells were incubated with
vehicle (lane 1) or PDGF (10 ng/ml) for 10 minutes at 37°C with or without (lane 2) ANP (10 M, lane 3; io, lane 4; 10 8, lane 5). Cleared cell lysates
were resolved by SDS-PAGE, transferred to PVDF membranes, and immunoblotted with anti-phosphotyrosine antibody (anti-PY). In lane 6, GC-A
antagonist HS-142-1 was co-incubated with ANP (10 ' M). Blots were reprobed with anti-PDGFR receptor antiserum (anti-PDGFR). Left margin
indicates Mr x 10 . (B)The effects of C-ANP423 (10-nM) and 8-bromo-cGMP (10 2 M) on PDGFR phosphorylation were compared to that of ANP(106 M). Left margin indicates Mr >< 10 . (C) Quantitative analysis. Results are mean so of three experiments. (D) The effect of ANP on PDGFR
autophosphorylation was examined under sodium orthovanadate (vanadate, 100 zM). Cells incubated with vanadate alone showed an increased tyrosine
phosphorylation of PDGFR as compared to those without vanadate (left). Cells incubated with vanadate and PDGF (10 ng/ml) for 10 minutes at 37°C
with or without ANP (10- M) arc shown on the right. Lysates were processed as described in (A). The left margin indicates that Mr X l0. Results
are a representative of two experiments.
and GC-B, has been shown to inhibit ANP-induced anti-mitogen-
esis in cultured mesangial cells [24]. These results demonstrate
that GC-A is responsible, at least in part, for the ANP-induced
anti-mitogenesis. In the present study, ANP's effect was mimicked
by 8-bromo-cGMP and inhibited by HS-142-1. In contrast,
C-ANP423, which selectively binds to C receptor, had little effect
on PDGFR autophosphorylation. These results further support
the role of GC-A in ANP's anti-proliferative action.
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Fig. 4. Effects of cGMP and PKG on PDGFR PTK activity.(A) Lectin affinity recovered proteins from unstimulated cell
(passages 3 to 5) lysate were assayed for PDGFR PTK
activity. PDGF (50 nglml) was added for 15 minutes at 0°C
prior to addition of 20 tM ATP with or without cGMP (2
.tM), PKG (0.5 units/j.tl) or both agents. After 30 minutes of
incubation at 22°C, reactions were stopped by the addition of
13 d of 5 X Laemmli SDS-PAGE sample buffer and
subjected to immunoblotting with anti—phosphotyrosine
antibody (anti-PY). Blots were reprobed with anti-PDGF /3
receptor antiserum (anti-PDGFR). Left margin indicates
Mr X io-. Results are representative of two experiments.
(B) Quantitative analysis by NIH Image. Results are means of two experiments. Lanes correspond to those in panel A.
(C) The same procedures were performed as (A) using
passaged cells (passages 8 to 9) that did not respond to ANP
or 8-bromo-cGMP in vivo. Left margin indicates Mr X iO.
Results are representative of three experiments. (D)
Quantitative analysis by NIH Image. Results are mean SE
of three experiments. Lanes correspond to those in panel B.
(E) Cell lysates were immunoprecipitated with anti-PDGF /3
receptor antiserum. Kinase reactions were performed on
protein A-Sepharose matrix beads. Left margin indicates
Mr x io—. Results are representative of two experiments.
The dose-dependency of ANP for PDGFR phosphorylation others exceed the circulating levels. It is known, however, that
suppression is in agreement with that for the inhibition of cultured vascular smooth muscle cells lose GC-A during the
mitogenesis. It should be pointed out that the concentrations of passage [18]. Similarly, they lose their responsiveness to cGMP
ANP and 8-bromo-cGMP employed in the present study and concurrently with the loss of PKG [171.PKG, as will be discussed
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below, is the principal receptor for cGMP in smooth muscle cells.
Thus, higher concentrations of ANP or 8-bromo-cGMP were
considered necessary to produce effects in cultured cells.
ANP's growth-inhibitory effects antagonizing PDGF have been
demonstrated in vascular smooth muscle cells as well as mesangial
cells [25]. Previous studies, however, have not examined the site of
ANP's action on PDGF cellular signaling. The present study
demonstrated that ANP inhibits PDGFR PTK. Reduction in
tyrosine phosphorylation of 110 kDa and 66 kDa protein was
also observed. It remains to be elucidated how the downstream
signaling pathways is affected. Recent work by Drummond-
Barbosa et a! suggests the dissociation of two activities of PDGFR
PTK in mitogenic signaling, namely, receptor autophosphoryla-
tion creating binding sites for SH2 domain-containing proteins
and tyrosine phosphorylation of other substrates [26]. Further-
more, Valgeirsdóttir et a! demonstrated that suramin, a polyan-
ionic compound that quenches PDGF-induced mitogenicity, un-
equally affected PDGF signaling molecules [27]. Thus, suramin
reduced the general level of tyrosine phosphotylation including
PDGFR. However, while suramin had no effect on activation of
P13-kinase or tyrosine phosphorylation of phospholipase C-y and
GAP, it markedly diminished the tyrosine phosphorylation of Shc
and complex formation with Grb2.
The fact that GC-A is responsible for the mediation of the
reduction in PDGFR autophosphorylation was further supported
by the in vitro study. Thus, cGMP inhibited PTK activity of
PDGFR purified by the lectin affinity step. The effect of cGMP
was not observed when PDGFR was prepared from the passaged
cells, which did not respond to ANP or 8-bromo-cGMP in vivo. As
discussed above, previous studies have reported that expression of
PKG decreases markedly upon each passage [17]. Taken together,
it appears that cGMP is not exerting its effect directly, but by
activating a target protein present in wheat germ agglutinin
eluate. Lack of response to cGMP in immunocomplex kinase
assay supports this hypothesis. Modes of action demonstrated for
cGMP include activation of PKGs, alteration of cGMP-regulated
ion channels, and regulation of cGMP-binding phosphodiester-
ases [28]. PKG is the major receptor protein for cGMP in vascular
smooth muscle cells. Little is known about the role of PKG in cell
proliferation. A recent study demonstrated that an inhibitor of
PKG blocked the loss of division potential in human fibroblasts,
suggesting a role for PKG in the induction of cellular senescence
[29]. Also, Yu et a! demonstrated that the anti-proliferative effect
of soluble guanylate cyclase activator in vascular smooth muscle
cells was antagonized by PKG inhibitor [30]. Finally, recent work
by Clementi et al demonstrated that nitric oxide inhibited PDGF-
stimulated phospholipase C activity via a PKG pathway in fibro-
blasts [31]. It is tempting to speculate that this inhibition of
phospholipase C is secondary to the reduced PTK activity of
PDGFR as shown in the present study.
In conclusion, the present data demonstrate that ANP inhibits
PDGFR PTK activity through GC-A. The action of ANP appears
to be mediated by PKG. This may be an important mechanism for
ANP's growth inhibitory action as well as that of nitrovasodilators.
A complex interaction may exist between cGMP pathways and
PDGFR tyrosine kinase system.
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